Advisors Asset Management Inc. Purchases 11,484 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advisors Asset Management Inc. raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 177,333 shares of the biopharmaceutical company’s stock after purchasing an additional 11,484 shares during the period. Advisors Asset Management Inc. owned 0.15% of Catalyst Pharmaceuticals worth $3,525,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Pacer Advisors Inc. boosted its stake in Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares during the period. Janus Henderson Group PLC boosted its position in shares of Catalyst Pharmaceuticals by 139.5% during the 1st quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after acquiring an additional 1,587,794 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after purchasing an additional 860,244 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Catalyst Pharmaceuticals by 101.1% in the first quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock worth $16,924,000 after purchasing an additional 533,802 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after purchasing an additional 287,300 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Trading Up 1.7 %

NASDAQ CPRX opened at $21.48 on Friday. The firm has a market cap of $2.56 billion, a PE ratio of 18.20, a price-to-earnings-growth ratio of 3.29 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27. The stock has a 50-day moving average of $21.10 and a 200-day moving average of $18.49.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Truist Financial raised their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.